Literature DB >> 22684569

Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts.

Dingyan Chen1, Yan Liu1, Wulong He2, Hongxing Wang3, Zengzhen Wang4.   

Abstract

This study examined the effects of combined administration of tyrosine, lecithin, L-glutamine and L-5-hydroxytryptophan (5-HTP) on heroin withdrawal syndromes and mental symptoms in detoxified heroin addicts. In the cluster-randomized placebo-controlled trial, 83 detoxified heroin addicts were recruited from a detoxification treatment center in Wuhan, China. Patients in the intervention group (n=41) were given the combined treatment with tyrosine, lecithin, L-glutamine and 5-HTP and those in the control group (n=42) were administered the placebo. The sleep status and the withdrawal symptoms were observed daily throughout the study, and the mood states were monitored pre- and post-intervention. The results showed that the insomnia and withdrawal scores were significantly improved over time in participants in the intervention group as compared with those in the control group. A greater reduction in tension-anxiety, depression-dejection, anger-hostility, fatigue-inertia and total mood disturbance, and a greater increase in their vigor-activity symptoms were found at day 6 in the intervention group than in the control group (all P<0.05). It was concluded that the neurotransmitter-precursor-supplement intervention is effective in alleviating the withdrawal and mood symptoms and it may become a supplementary method for patients' recovery from heroin addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684569     DOI: 10.1007/s11596-012-0073-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  32 in total

1.  Nutritional status of drug addicts undergoing detoxification: prevalence of malnutrition and influence of illicit drugs and lifestyle.

Authors:  S K Nazrul Islam; Kazi Jahangir Hossain; Afsaruddin Ahmed; Monira Ahsan
Journal:  Br J Nutr       Date:  2002-11       Impact factor: 3.718

2.  Lecithin in mania: a preliminary report.

Authors:  B M Cohen; A L Miller; J F Lipinski; H G Pope
Journal:  Am J Psychiatry       Date:  1980-02       Impact factor: 18.112

3.  Prospective and retrospective reports of mood states before relapse to substance use.

Authors:  D C Hodgins; N el-Guebaly; S Armstrong
Journal:  J Consult Clin Psychol       Date:  1995-06

4.  Effects of β-adrenergic receptor blockade on drug-related memory reconsolidation in abstinent heroin addicts.

Authors:  Li-Yan Zhao; Li-Li Sun; Jie Shi; Peng Li; Yan Zhang; Lin Lu
Journal:  Drug Alcohol Depend       Date:  2011-04-29       Impact factor: 4.492

5.  The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a 'dual diagnosis'?

Authors:  Icro Maremmani; Matteo Pacini; Pier Paolo Pani; Giulio Perugi; Joseph Deltito; Hagop Akiskal
Journal:  Ann Gen Psychiatry       Date:  2007-11-13       Impact factor: 3.455

6.  [Insomnia, serotonin and depression].

Authors:  Sh V Vashadze
Journal:  Georgian Med News       Date:  2007-09

7.  Lecithin in the treatment of mania: double-blind, placebo-controlled trials.

Authors:  B M Cohen; J F Lipinski; R I Altesman
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

8.  Living as a drug addict in Oslo, Norway--a study focusing on nutrition and health.

Authors:  M Saeland; M Haugen; F-L Eriksen; A Smehaugen; M Wandel; T Böhmer; A Oshaug
Journal:  Public Health Nutr       Date:  2008-06-13       Impact factor: 4.022

9.  Effects of phosphatidylcholine administration to rats on choline in blood and choline and acetylcholine in brain.

Authors:  R S Jope
Journal:  J Pharmacol Exp Ther       Date:  1982-02       Impact factor: 4.030

10.  Administration of phosphatidylcholine increases brain acetylcholine concentration and improves memory in mice with dementia.

Authors:  S Y Chung; T Moriyama; E Uezu; K Uezu; R Hirata; N Yohena; Y Masuda; T Kokubu; S Yamamoto
Journal:  J Nutr       Date:  1995-06       Impact factor: 4.798

View more
  7 in total

1.  Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marcelo Febo; Lyle Fried; Mona Li; Kristina Dushaj; Eric R Braverman; Thomas McLaughlin; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-12-29       Impact factor: 2.164

2.  Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Elizabeth Stuller; David Miller; John Giordano; Siobhan Morse; Lee McCormick; William B Downs; Roger L Waite; Debmalya Barh; Dennis Neal; Eric R Braverman; Raquel Lohmann; Joan Borsten; Mary Hauser; David Han; Yijun Liu; Manya Helman; Thomas Simpatico
Journal:  J Addict Res Ther       Date:  2012-11-27

3.  Hypothesizing that a Pro-Dopaminergic Regulator (KB220z Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.

Authors:  Kenneth Blum; Debra Whitney; Lye Fried; Marcelo Febo; Roger L Waite; Eric R Braverman; Kristina Dushaj; Mona Li; John Giordano; Zsolt Demetrovics; Rajendra D Badgaiyan
Journal:  Clin Med Rev Case Rep       Date:  2016-08-16

4.  Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).

Authors:  Blum Kenneth; Modestino J Edward; Gondre Lewis C Marjorie; Baron David; Steinberg Bruce; Thanos K Panayotis; Downs B William; Siwicki Davis; Lott Lisa; Braverman R Eric; Moran Mark; Miller David; Fried Lyle; Badgaiyan D Rajendra
Journal:  CPQ Neurol Psychol       Date:  2018-12-04

5.  Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis.

Authors:  Kenneth Blum; Jag Khalsa; Jean Lud Cadet; David Baron; Abdalla Bowirrat; Brent Boyett; Lisa Lott; Raymond Brewer; Marjorie Gondré-Lewis; Gregory Bunt; Shan Kazmi; Mark S Gold
Journal:  Front Psychiatry       Date:  2021-03-30       Impact factor: 4.157

6.  Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial.

Authors:  Dongming Wang; Wenzhen Li; Yang Xiao; Wulong He; Weiquan Wei; Longyu Yang; Jincong Yu; Fujian Song; Zengzhen Wang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids.

Authors:  Douglas J Hermes; Ian R Jacobs; Megan C Key; Alexis F League; Barkha J Yadav-Samudrala; Changqing Xu; Virginia D McLane; Sara R Nass; Wei Jiang; Rick B Meeker; Bogna M Ignatowska-Jankowska; Aron H Lichtman; Zibo Li; Zhanhong Wu; Hong Yuan; Pamela E Knapp; Kurt F Hauser; Sylvia Fitting
Journal:  J Neuroinflammation       Date:  2020-11-18       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.